Evidence map›Paper›PMID 31476841›Full record

ArticleBiomolecules & therapeutics2020

A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells.

Sachan Richa, Prasanta Dey, Chaeun Park, Jungho Yang, Ji Yeon Son, Jae Hyeon Park, Su Hyun Lee, Mee-Young Ahn, In Su Kim, Hyung Ryong Moon and 1 more

Abstract read
In one paragraph

Article in Biomolecules & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sachan RichaSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Prasanta DeySchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Chaeun ParkCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Jungho YangCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Ji Yeon SonSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Jae Hyeon ParkSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Su Hyun LeeSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Mee-Young AhnMajor in Pharmaceutical Engineering, Division of Bioindustry, College of Medical and Life Sciences, Silla University, Busan 46958, Republic of Korea.
In Su KimSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Hyung Ryong MoonCollege of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
Hyung Sik KimSchool of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Sungkyunkwan University · KRPusan National University · KRSilla University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone deacetylase (HDAC) inhibitors represent a novel class of anticancer agents, which can be used to inhibit cell proliferation and induce apoptosis in several types of cancer cells. In this study, we investigated the anticancer activity of MHY4381, a newly synthesized HDAC inhibitor, against human prostate cancer cell lines and compared its efficacy with that of suberoylanilide hydroxamic acid (SAHA), a well-known HDAC inhibitor. We assessed cell viability, apoptosis, cell cycle regulation, and other biological effects in the prostate cancer cells. We also evaluated a possible mechanism of MHY4381 on the apoptotic cell death pathway. The IC

Indexed as

ApoptosisHDAC inhibitorMHY4381Prostate cancerReactive oxygen species

Identifiers

PMID31476841
PMCPMC7059815
OpenAlexW2972062469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.